Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
anticipated to increase during the first half of this century. Chemotherapy is
the mainstay of treatment, yet sufficiently robust evidence to substantiate
the current standard of care has emerged only in the past 5 years. Methods:
A retrospective cohort study of 100 MPM patients referred to NCI, Cairo
University in 3 years. Detailed data, Pearson’s Chi (x2) square and Logistic
regression model were used for statistical analysis. Results: We found a
statistical significant relation between age ( 0.005), male gender (0.002),
endemic area residence( 0.001), industrial workers ( 0.018), duration of
exposure (0.04), smokers (0.009), Simian virus ( 0.019), P53 ( 0.001), RbP
(0.001), PS ( 0.0.16) and development of high grade toxicity of platinum based
chemotherapy.
Median age = 46 years, only 17% of cases developed high grade toxicity
complications of platinum based chemotherapy. Males were 59% of cases.
PS, residence, smoking, occupation, history of asbestos exposure, family
history, simian virus, P53, Rbp, dyspnea, chest pain, cough, expectoration,
haemoptysis, weight loss, fatigue, metastatic symptoms, chronic lung
infection, Tuberculous pleuritic, effusion, pleural thickening, Tracheal shift,
TNM staging, surgical operations, pathological staging, radiotherapy ,cause
of death and chemotherapy toxicity are assessed in our patients. Conclusion:
Many factors predict high grade chemotherapy toxicity. So, search for target
therapy and immunotherapy instead of chemotherapy in this selected group
can improve both quality of life and response rate.
POSTER SESSION 1 - P1.01: EPIDEMIOLOGY, TOBACCO CONTROL AND CESSATION/
PREVENTION
PROGNOSTIC FACTORS, TREATMENT –
MONDAY, DECEMBER 5, 2016
higher ECOG values. Methods: Between January 2004 and December 2013, all
patients diagnosed with a pathology of SCLC and NSCLC at National Institute
of Oncology at Paraguay were analyzed retrospectively. ECOG performance
status were recorded and SPSS 20 was used to analyze with logistic Binary
regression Results: We studied 478 subjects. At age mean 60,40 [95% CI 59,45
to 61,34 ] years and ECOG performance status mean 2,13 [95% CI 2,06 to 2,20]
points. Bivariate correlations show no relation with age, gender, living place,
work, smoking, alcohol consumption, histopathology of lung cancer only with
motive of consultation and clinical severity. In our model of predicting a ECOG
3 to 5 adding first motive of consultation show a Nagelkerke R2: 0.14, Hosmer
y Lemeshow P: 0.95. Adding to the model clinical severity Nagelkerke R2: 0.07
Hosmer y Lemeshow P: 1.0. Variables in our predicting model show at clinical
severity IIB stage OR:6,62 [95% CI 1,13 to 38,52 P=0.035], clinical severity IIIA
stage OR: 3.85 [95% CI 1,18 to 12.51 P=0.025],clinical severity IIIB stage OR:4,49
[95% CI 1,87 to 10,78 P=0.001]. At limited-stage SCLC clinical severity OR: 10,12
[95% CI 1,88 to 54,34 P=0.007]. At first motive of consultation chest paint OR:
3,13 [95% CI 1,38 to 7,11 P=0.006]. Cough OR: 2,30 [95% CI 1,11 to 4,76 P=0.024].
Palpable Tumoral mass OR: 8,35 [95% CI 1,65 to 42,07 P=0.010]. Conclusion:
Regardless our expectations about relation of disability of patient with lung
cancer about place of living, work, gender, age this variables show no relation
with ECOG at 3 to 5. In Our review we found a prediction model with clinical
severity adding 7% to prognostic of limited self-care and by adding to the
model first motive of consultation a 14% of prognostic of worst ECOG status.
If first consultation motive is chest pain, cough or palpable tumoral mass,
this are strongly related with worst ECOG values. As a conclusion most of our
patients are diagnostic in advance clinical stages with a bad performance
status which will limited our options to treatment. All of these can be related
with a late consultation or a late detection of the disease.
Keywords: Lung neoplasm, quality of life, Neoplasm Staging
P1.01-050 OVERALL SURVIVAL IN ADVANCED LUNG CANCER
PATIENTS TREATED AT ONCOSALUD-AUNA
Alfredo Aguilar 1 , Claudio Flores 2 , Luis Mas 1 , José María Gutierrez 1 , Luis
Pinillos 3 , Carlos Vallejos 1
1 Department of Medical Oncology, Oncosalud - Auna, Lima/Peru, 2 Dirección
Científica Y Académica, Oncosalud - Auna, Lima/Peru, 3 Radioncología - Auna, Lima/
Peru
Background: Lung cancer still remains as the principal death cause in many
regions around the world. Unfortunate, between 60-70% of patients are
diagnosed with advanced disease (clinical stage IIIB-IV). We report the overall
survival of advanced lung cancer in patients treated at a private institution
(Oncosalud – AUNA). Methods: We analyzed data of 75 patients with
advanced lung cancer and treated at Oncosalud-AUNA between 2013-2014.
Overall survival was determinate using Kaplan-Meier method and survival
curves comparison were performed using logrank test. Results: The median
age was 70 years (range: 39-91) and 49% of patients were women. In patients
with clinical stage IV, the metastatic sites were generally brain (28%),
osseous (18%), cervical and supraclavicular (14%). The 66.7% of patients
received chemotherapy with/without radiotherapy, 9% radiotherapy only
and 24% non-treatment. In patients previously treated with chemotherapy,
52% received targeted therapy. The 77% of patients hab died, the follow-up
median of survivors was 23 months (CI95%: 17-29), survival median was 9.6
months (CI95%. 5.6-13.5) and 1 and 2 years survival rate were 38% and 23%,
respectively. The survival rate at 1 and 2 years in those receiving targeted
therapy ware 65% and 43%, and those who did not receive were 35% and 10%.
The overall survival present a difference regarding to ECOG scale (p = 0.015)
and CYFRA 21.2 (p = 0.04). Conclusion: Overall survival for our patients is
similar to other series. Patients under ECOG scale